Mumbai: Zydus Cadila has filed an Investigational New Drug application with Drugs Controller General of India for ZYT 1, which is used to prevent heart attack and stroke.
The ZYT 1 molecule is designed and developed at the Zydus research centre, Cadila Healthcare - the flagship company of Zydus Cadila Group - said in a filing to Bombay Stock Exchange.
“There is currently a huge unmet need for new therapies in treating dyslipidemia patients. In ZYT 1, we see an interesting possibility that can adequately bridge this gap and usher in significant improvement in meeting treatment goals,” Zydus Cadila Chairman and Managing Director Pankaj Patel said.
The molecule has demonstrated beneficial effect on low-density lipoprotein cholesterol, commonly known as the bad cholesterol, and triglycerides which is the chemical compound that is formed in the animal body from fat in the diet.
Cardiovascular segment is the largest therapeutic segment in the world of pharmaceutical market and treatment of dyslipidemia which is imbalance in cholesterol metabolism represents a major sector of this market, which is expected to grow from $36 billion in 2007 to $42 billion in 2012.
Zydus Cadila now has six candidates in various stages of clinical development, with two candidates in Phase II clinical development.
Shares of the company were trading at Rs253.05, down 6.17% in the morning trade on the BSE.